Merial GmbH, Kathrinenhof Research Center, 83101 Rohrdorf, Germany.
Universiteti Bujqësor, Fakulteti i Mjeksise Veterinare, Kodër Kamëz, Tirana, Albania.
Vet Parasitol. 2014 Apr 28;202(1-2):45-8. doi: 10.1016/j.vetpar.2014.02.038.
Infection with urinary capillarid bladder worms has been observed in cats worldwide. Although considered as generally causing no or little harm, infection with urinary capillarids may be associated with clinical disease which requires an appropriate treatment including the use of anthelmintics. Therefore, the efficacy of a novel topical combination formulation of fipronil 8.3% (w/v), (S)-methoprene 10% (w/v), eprinomectin 0.4% (w/v), and praziquantel 8.3% (w/v) (BROADLINE(®), Merial) was evaluated against urinary capillarids in naturally infected cats. Sixteen European Short Hair cats (5 male, 11 female) with capillarid eggs in their urine pre-treatment were included in the study. At the time of treatment, the cats were approximately ten months to eight years old and weighed 1.6-3.6 kg. Cats were ranked based on decreasing bodyweight and then randomly allocated within replicates of two animals to one of the treatment groups. Each cat in the treated group received one topical application of the combination product at the minimum therapeutic dose of 0.12 mL/kg body weight delivering 10mg fipronil+12 mg (S)-methoprene+0.5mg eprinomectin+10mg praziquantel per kilogram of body weight while the cats allocated to the control group remained untreated. For parasite recovery, identification and count, cats were euthanized humanely 14 days after treatment. All untreated cats harboured Capillaria plica in their urinary bladders (range 4-12), while no capillarids were recovered from the eight treated cats. Thus, the efficacy of the novel topical combination against C. plica was 100%. All cats accepted the treatment well based on post-treatment observations and daily observations thereafter. No adverse events or other health problems were observed during the study.
全世界的猫都有感染泌尿道毛细线虫的情况。虽然这种感染通常不会造成伤害或只有轻微伤害,但感染泌尿道毛细线虫可能与临床疾病有关,需要进行适当的治疗,包括使用驱虫药。因此,评估了一种新型局部组合制剂氟虫腈 8.3%(w/v)、(S)-灭幼脲 10%(w/v)、依普菌素 0.4%(w/v)和吡喹酮 8.3%(w/v)(BROADLINE(®),梅里亚)对自然感染泌尿道毛细线虫的猫的疗效。研究纳入了 16 只欧洲短毛猫(5 只雄性,11 只雌性),这些猫在治疗前的尿液中都有毛细线虫卵。在治疗时,这些猫大约 10 个月至 8 岁,体重 1.6-3.6 公斤。根据体重递减对猫进行排序,然后将其随机分配到两个重复的治疗组中的一组。每个接受治疗的组的猫都接受了一次该组合产品的局部应用,剂量为最低治疗剂量 0.12 mL/kg 体重,每公斤体重给予 10mg 氟虫腈+12mg(S)-灭幼脲+0.5mg 依普菌素+10mg 吡喹酮,而分配到对照组的猫则未接受治疗。为了进行寄生虫回收、鉴定和计数,在治疗后 14 天对猫进行了安乐死。所有未经治疗的猫的膀胱中都有 Capillaria plica(范围为 4-12),而在接受治疗的 8 只猫中没有回收毛细线虫。因此,该新型局部组合制剂对 C. plica 的疗效为 100%。根据治疗后的观察和此后的日常观察,所有猫都很好地接受了治疗。在研究期间,没有观察到不良事件或其他健康问题。